{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T20:58:52Z","timestamp":1794085132198,"version":"4.8.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82400186"],"award-info":[{"award-number":["82400186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BK20240269"],"award-info":[{"award-number":["BK20240269"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jiangsu Province Young Scientific and Technological Talents Promotion Program","award":["JSYJ-2025-728"],"award-info":[{"award-number":["JSYJ-2025-728"]}]},{"name":"Feihong Program of Nanjing Hospital of Chinese Medicine","award":["FHJH202402"],"award-info":[{"award-number":["FHJH202402"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04731-5","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:49:04Z","timestamp":1782182944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ferumoxytol enhances NF-\u03baB-responsive GBA-targeted ferroptosis gene therapy in acute myeloid leukemia"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8675-6762","authenticated-orcid":false,"given":"Tao","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"4731_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41420-022-01193-0","volume":"8","author":"Y Chen","year":"2022","unstructured":"Chen Y, Li J, Xu L, G\u0103man M-A, Zou Z. The genesis and evolution of acute myeloid leukemia stem cells in the microenvironment: From biology to therapeutic targeting. Cell Death Discovery. 2022;8:397.","journal-title":"Cell Death Discovery"},{"key":"4731_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16:29.","journal-title":"J Hematol Oncol"},{"key":"4731_CR3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s11912-022-01299-9","volume":"24","author":"DC de Leeuw","year":"2022","unstructured":"de Leeuw DC, Ossenkoppele GJ, Janssen JJ. Older patients with acute myeloid leukemia deserve individualized treatment. Curr Oncol Rep. 2022;24:1387\u2013400.","journal-title":"Curr Oncol Rep"},{"key":"4731_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108:353.","journal-title":"Haematologica"},{"key":"4731_CR5","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.3390\/cancers14143557","volume":"14","author":"B Di Francesco","year":"2022","unstructured":"Di Francesco B, Verzella D, Capece D, Vecchiotti D, Di Vito Nolfi M, Flati I, Cornice J, Di Padova M, Angelucci A, Alesse E. NF-\u03baB: a druggable target in acute myeloid leukemia. Cancers. 2022;14:3557.","journal-title":"Cancers"},{"key":"4731_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.22203\/eCM.v023a08","volume":"23","author":"K Wuertz","year":"2012","unstructured":"Wuertz K, Vo N, Kletsas D, Boos N. Inflammatory and catabolic signalling in intervertebral discs: The roles of NF-kB and MAP Kinases. Eur Cell Mater. 2012;23:103\u201320.","journal-title":"Eur Cell Mater"},{"key":"4731_CR7","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1097\/CM9.0000000000001628","volume":"134","author":"C Dong","year":"2021","unstructured":"Dong C, Zhang N-J, Zhang L-J. Oxidative stress in leukemia and antioxidant treatment. Chin Med J. 2021;134:1897\u2013907.","journal-title":"Chin Med J"},{"key":"4731_CR8","doi-asserted-by":"publisher","first-page":"156672","DOI":"10.1016\/j.cyto.2024.156672","volume":"180","author":"M Yan","year":"2024","unstructured":"Yan M, Chen X, Ye Q, Li H, Zhang L, Wang Y. IL-33-dependent NF-\u03baB activation inhibits apoptosis and drives chemoresistance in acute myeloid leukemia. Cytokine. 2024;180:156672.","journal-title":"Cytokine"},{"key":"4731_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s12032-025-03148-8","volume":"43","author":"M Wang","year":"2025","unstructured":"Wang M, Li W, Luo C, Cao Y, Lu Z, Zhu J, Xiang M, Liao P, Li J. RPPH1 promotes the progression of High-Risk acute myeloid leukemia through NF-\u03baB signaling and Th17 expression. Med Oncol. 2025;43:30.","journal-title":"Med Oncol"},{"key":"4731_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","volume":"9","author":"Q Guo","year":"2024","unstructured":"Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, Zeng C, Zhou T, Zhang J. NF-\u03baB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target therapy. 2024;9:53.","journal-title":"Signal Transduct Target therapy"},{"key":"4731_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1089\/ars.2022.0179","volume":"40","author":"V Consoli","year":"2024","unstructured":"Consoli V, Fallica AN, Sorrenti V, Pittala V, Vanella L. Novel insights on ferroptosis modulation as potential strategy for cancer treatment: when nature kills. Antioxid Redox Signal. 2024;40:40\u201385.","journal-title":"Antioxid Redox Signal"},{"key":"4731_CR12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.15212\/bioi-2020-0039","volume":"2","author":"D Xu","year":"2021","unstructured":"Xu D, Lu Y, Li Y, Li S, Wang Z, Wang J. Ferroptosis resistance in cancer: an emerging crisis of new hope. BIO Integr. 2021;2:22.","journal-title":"BIO Integr"},{"key":"4731_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21:47.","journal-title":"Mol Cancer"},{"key":"4731_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1186\/s12951-022-01663-8","volume":"20","author":"T Luo","year":"2022","unstructured":"Luo T, Wang Y, Wang J. Ferroptosis assassinates tumor. J Nanobiotechnol. 2022;20:467.","journal-title":"J Nanobiotechnol"},{"key":"4731_CR15","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1111\/febs.16034","volume":"289","author":"L Shi","year":"2022","unstructured":"Shi L, Liu Y, Li M, Luo Z. Emerging roles of ferroptosis in the tumor immune landscape: from danger signals to anti-tumor immunity. FEBS J. 2022;289:3655\u201365.","journal-title":"FEBS J"},{"key":"4731_CR16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41586-024-07623-6","volume":"631","author":"HK Co","year":"2024","unstructured":"Co HK, Wu C-C, Lee Y-C, Chen S-h. Emergence of large-scale cell death through ferroptotic trigger waves. Nature. 2024;631:654\u201362.","journal-title":"Nature"},{"key":"4731_CR17","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1038\/s41467-021-25632-1","volume":"12","author":"J Gao","year":"2021","unstructured":"Gao J, Luo T, Wang J. Gene interfered-ferroptosis therapy for cancers. Nat Commun. 2021;12:5311.","journal-title":"Nat Commun"},{"key":"4731_CR18","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2217\/nnm-2022-0246","volume":"17","author":"L Wu","year":"2022","unstructured":"Wu L, Wang C, Li Y. Iron oxide nanoparticle targeting mechanism and its application in tumor magnetic resonance imaging and therapy. Nanomedicine. 2022;17:1567\u201383.","journal-title":"Nanomedicine"},{"key":"4731_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.22203\/eCM.v048a04","volume":"48","author":"XL Zhu","year":"2024","unstructured":"Zhu XL, Fu QC, Jiang LF. Iron oxide nanoparticles for diagnosing and treating degenerative orthopaedic diseases: a review. Eur Cell Mater. 2024;48:45\u201365.","journal-title":"Eur Cell Mater"},{"key":"4731_CR20","doi-asserted-by":"crossref","unstructured":"Hosseinkazemi H, Samani S, O\u2019Neill A, Soezi M, Moghoofei M, Azhdari MH, Aavani F, Nazbar A, Keshel SH, Doroudian M. Applications of iron oxide nanoparticles against breast cancer. Journal of Nanomaterials 2022, 2022:6493458.","DOI":"10.1155\/2022\/6493458"},{"key":"4731_CR21","doi-asserted-by":"publisher","first-page":"70","DOI":"10.15212\/bioi-2022-0016","volume":"4","author":"GS Lin","year":"2023","unstructured":"Lin GS, Lin H, Yuan Z, Liu G. In vivo Iron-Based Coordination Assembly for Disease Diagnosis and Treatment. BIO Integr. 2023;4:70.","journal-title":"BIO Integr"},{"key":"4731_CR22","doi-asserted-by":"crossref","unstructured":"Wang Q, Qian W, Han Y, Mao Y, Gao Z, Chen Y, Zeng X, Lu H, Jiang L, Li J. Ferumoxytol promotes haematopoietic stem cell post-injury regeneration as a reactive oxygen species scavenger. Nat Nanotechnol 2025;20:1\u201311.","DOI":"10.1038\/s41565-025-01907-2"},{"key":"4731_CR23","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41565-019-0406-1","volume":"14","author":"V Trujillo-Alonso","year":"2019","unstructured":"Trujillo-Alonso V, Pratt EC, Zong H, Lara-Martinez A, Kaittanis C, Rabie MO, Longo V, Becker MW, Roboz GJ, Grimm J, Guzman ML. FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. Nat Nanotechnol. 2019;14:616\u201322.","journal-title":"Nat Nanotechnol"},{"key":"4731_CR24","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1080\/10985549.2025.2494762","volume":"45","author":"R Zhang","year":"2025","unstructured":"Zhang R, Vooijs MA, Keulers TG. Key Mechanisms in Lysosome Stability, Degradation and Repair. Mol Cell Biol. 2025;45:212\u201324.","journal-title":"Mol Cell Biol"},{"key":"4731_CR25","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.tibs.2021.07.003","volume":"46","author":"F Rizzollo","year":"2021","unstructured":"Rizzollo F, More S, Vangheluwe P, Agostinis P. The lysosome as a master regulator of iron metabolism. Trends Biochem Sci. 2021;46:960\u201375.","journal-title":"Trends Biochem Sci"},{"key":"4731_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/jcp.30928","volume":"238","author":"S Patra","year":"2023","unstructured":"Patra S, Patil S, Klionsky DJ, Bhutia SK. Lysosome signaling in cell survival and programmed cell death for cellular homeostasis. J Cell Physiol. 2023;238:287\u2013305.","journal-title":"J Cell Physiol"},{"key":"4731_CR27","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41531-022-00397-6","volume":"8","author":"A Navarro-Romero","year":"2022","unstructured":"Navarro-Romero A, Fernandez-Gonzalez I, Riera J, Montpeyo M, Albert-Bayo M, Lopez-Royo T, Castillo-Sanchez P, Carnicer-Caceres C, Arranz-Amo JA, Castillo-Ribelles L. Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology. NPJ Parkinson\u2019s disease. 2022;8:126.","journal-title":"NPJ Parkinson\u2019s disease"},{"key":"4731_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/cells12010191","volume":"12","author":"E Pradas","year":"2023","unstructured":"Pradas E, Martinez-Vicente M. The consequences of GBA deficiency in the autophagy\u2013lysosome system in Parkinson\u2019s disease associated with GBA. Cells. 2023;12:191.","journal-title":"Cells"},{"key":"4731_CR29","unstructured":"Boer DEC. Glucocerebrosidase and glycolipids: In and beyond the lysosome. Leiden University; 2021."},{"key":"4731_CR30","doi-asserted-by":"crossref","unstructured":"Luo T, Wang Y, Tang H, Zhou F, Chen Y, Pei B, Wang J. An AAV-Based NF-\u03baB-Targeting Gene Therapy (rAAV-DMP-miR533) to Inflammatory Diseases. J Inflamm Res 2022;15:3447\u201366.","DOI":"10.2147\/JIR.S362732"},{"key":"4731_CR31","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.exphem.2007.07.018","volume":"35","author":"S Michelfelder","year":"2007","unstructured":"Michelfelder S, Lee MK, deLima-Hahn E, Wilmes T, Kaul F, Muller O, Kleinschmidt JA, Trepel M. Vectors selected from adeno-associated viral display peptide libraries for leukemia cell-targeted cytotoxic gene therapy. Exp Hematol. 2007;35:1766\u201376.","journal-title":"Exp Hematol"},{"key":"4731_CR32","doi-asserted-by":"publisher","first-page":"116946","DOI":"10.1016\/j.ejmech.2024.116946","volume":"280","author":"L Tong","year":"2024","unstructured":"Tong L, Zha M-L, Hu J, Li H-Y, Kuai L, Li B, Dang Y, Zhao Q, Liao R, Lin G-Q. Adenanthin exhibits anti-inflammatory effects by covalently targeting the p65 subunit in the NF-\u03baB signaling pathway. Eur J Med Chem. 2024;280:116946.","journal-title":"Eur J Med Chem"},{"key":"4731_CR33","doi-asserted-by":"crossref","unstructured":"Luan X, Zou Z, Chen J, Hao Z, Hu H, Chen C, Lv H, Du Y, Pei X, Liu S. Pyxinol derivative suppresses LPS-induced inflammation by targeting the p65-p50 heterodimer. Bioorg Chem 2025;167:109269.","DOI":"10.1016\/j.bioorg.2025.109269"},{"key":"4731_CR34","doi-asserted-by":"publisher","first-page":"851135","DOI":"10.3389\/fnagi.2022.851135","volume":"14","author":"W Zheng","year":"2022","unstructured":"Zheng W, Fan D. Glucocerebrosidase mutations cause mitochondrial and lysosomal dysfunction in Parkinson\u2019s disease: pathogenesis and therapeutic implications. Front Aging Neurosci. 2022;14:851135.","journal-title":"Front Aging Neurosci"},{"key":"4731_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymeth.2016.04.003","volume":"103","author":"X Bofill-De Ros","year":"2016","unstructured":"Bofill-De Ros X, Gu S. Guidelines for the optimal design of miRNA-based shRNAs. Methods. 2016;103:157\u201366.","journal-title":"Methods"},{"key":"4731_CR36","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.celrep.2013.11.020","volume":"5","author":"C Fellmann","year":"2013","unstructured":"Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, Lai D, Barbosa I, Kwon J, Guan Y. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep. 2013;5:1704\u201313.","journal-title":"Cell Rep"},{"key":"4731_CR37","doi-asserted-by":"publisher","first-page":"e1640","DOI":"10.1002\/wrna.1640","volume":"12","author":"A Kotowska-Zimmer","year":"2021","unstructured":"Kotowska-Zimmer A, Pewinska M, Olejniczak M. Artificial miRNAs as therapeutic tools: Challenges and opportunities. Wiley Interdisciplinary Reviews: RNA. 2021;12:e1640.","journal-title":"Wiley Interdisciplinary Reviews: RNA"},{"key":"4731_CR38","doi-asserted-by":"publisher","first-page":"7783","DOI":"10.3390\/ijms22157783","volume":"22","author":"VV Klimontov","year":"2021","unstructured":"Klimontov VV, Saik OV, Korbut AI. Glucose variability: how does it work? Int J Mol Sci. 2021;22:7783.","journal-title":"Int J Mol Sci"},{"key":"4731_CR39","doi-asserted-by":"publisher","first-page":"154470","DOI":"10.1016\/j.cej.2024.154470","volume":"497","author":"J Yang","year":"2024","unstructured":"Yang J, Zhu J, Ren B, Cai H, Li Z, Fan Q, Xiong W, Feng J, Yan C, Wen G. A hollow mesoporous iron oxide nanoparticle to strengthen Fenton reaction and weaken antioxidant defense systems for high efficacy tumor ferroptosis therapy. Chem Eng J. 2024;497:154470.","journal-title":"Chem Eng J"},{"key":"4731_CR40","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/ki.2011.18","volume":"79","author":"M-M Zhao","year":"2011","unstructured":"Zhao M-M, Xu M-J, Cai Y, Zhao G, Guan Y, Kong W, Tang C, Wang X. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. Kidney Int. 2011;79:1071\u20139.","journal-title":"Kidney Int"},{"key":"4731_CR41","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.bcp.2006.04.011","volume":"72","author":"G Gloire","year":"2006","unstructured":"Gloire G, Legrand-Poels S, Piette J. NF-\u03baB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol. 2006;72:1493\u2013505.","journal-title":"Biochem Pharmacol"},{"key":"4731_CR42","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.neulet.2014.10.041","volume":"584","author":"KP Doyle","year":"2015","unstructured":"Doyle KP, Quach LN, D\u2019Arceuil HE, Buckwalter MS. Ferumoxytol administration does not alter infarct volume or the inflammatory response to stroke in mice. Neurosci Lett. 2015;584:236\u201340.","journal-title":"Neurosci Lett"},{"key":"4731_CR43","doi-asserted-by":"publisher","first-page":"204062072110060","DOI":"10.1177\/20406207211006022","volume":"12","author":"H Khan","year":"2021","unstructured":"Khan H, May P, Kuo E, Pai P, Boles K, McGee A, Dang T, Schmit J. Safety and efficacy of a single total dose infusion (1020\u00a0mg) of ferumoxytol. Therapeutic Adv Hematol. 2021;12:20406207211006022.","journal-title":"Therapeutic Adv Hematol"},{"issue":"7","key":"4731_CR44","doi-asserted-by":"publisher","first-page":"e17888","DOI":"10.1002\/mp.17888","volume":"52","author":"DY Chang","year":"2025","unstructured":"Chang DY, Speth JP, Scarpelli ML. Evaluating the theranostic potential of ferumoxytol when combined with radiotherapy in a mammary dual tumor mouse model. Med Phys. 2025;52(7):e17888.","journal-title":"Med Phys"},{"key":"4731_CR45","doi-asserted-by":"publisher","first-page":"2302773","DOI":"10.1002\/adhm.202302773","volume":"13","author":"M Long","year":"2024","unstructured":"Long M, Li Y, He H, Gu N. The story of ferumoxytol: synthesis production, current clinical applications, and therapeutic potential. Adv Healthc Mater. 2024;13:2302773.","journal-title":"Adv Healthc Mater"},{"key":"4731_CR46","doi-asserted-by":"publisher","first-page":"574","DOI":"10.14740\/wjon2676","volume":"16","author":"H Al Sadoun","year":"2025","unstructured":"Al Sadoun H, Alamoudi F, Alamoudi N, Tayeb H, Felimban R, Alserihi R, Yasin EB, Khan R, Noorwali AW. Understanding the Role of All-Trans Retinoic Acid in Acute Myeloid Leukemia Cells. World J Oncol. 2025;16:574\u201386.","journal-title":"World J Oncol"},{"key":"4731_CR47","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3324\/haematol.2018.212886","volume":"105","author":"C Annageldiyev","year":"2020","unstructured":"Annageldiyev C, Gowda K, Patel T, Bhattacharya P, Tan SF, Iyer S, Desai D, Dovat S, Feith DJ, Loughran TP Jr., et al. The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia. Haematologica. 2020;105:687\u201396.","journal-title":"Haematologica"},{"key":"4731_CR48","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, Jabbour E, Schiffer CA, Lang A, Ravandi F. Acute myeloid leukemia management and research in 2025. Cancer J Clin. 2025;75:46\u201367.","journal-title":"Cancer J Clin"},{"key":"4731_CR49","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/clpt.2011.122","volume":"90","author":"S Clarke","year":"2011","unstructured":"Clarke S, Chua W, Moore M, Kao S, Phan V, Tan C, Charles K, McMillan D. Use of inflammatory markers to guide cancer treatment. Clin Pharmacol Ther. 2011;90:475\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"4731_CR50","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.jgo.2019.03.014","volume":"11","author":"KP Loh","year":"2020","unstructured":"Loh KP, Tooze JA, Nicklas BJ, Kritchevsky SB, Williamson JD, Ellis LR, Powell BL, Pardee TS, Goyal NG, Klepin HD. Inflammatory biomarkers, geriatric assessment, and treatment outcomes in acute myeloid leukemia. J geriatric Oncol. 2020;11:410\u20136.","journal-title":"J geriatric Oncol"},{"key":"4731_CR51","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1182\/bloodadvances.2024015397","volume":"9","author":"HJ Iland","year":"2025","unstructured":"Iland HJ, Reynolds J, Boddy AV, Schultz HB, Khoo L, Fleming S, Lane SW, Weber N, Gasiorowski R, Armytage T. ALLG APML5: bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL. Blood Adv. 2025;9:1476\u201384.","journal-title":"Blood Adv"},{"key":"4731_CR52","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fonc.2017.00003","volume":"7","author":"N Ramamonjisoa","year":"2017","unstructured":"Ramamonjisoa N, Ackerstaff E. Characterization of the tumor microenvironment and tumor\u2013stroma interaction by non-invasive preclinical imaging. Front Oncol. 2017;7:3.","journal-title":"Front Oncol"},{"key":"4731_CR53","doi-asserted-by":"publisher","first-page":"e112067","DOI":"10.15252\/embj.2022112067","volume":"42","author":"R Missiaen","year":"2023","unstructured":"Missiaen R, Lesner NP, Simon MC. HIF: a master regulator of nutrient availability and metabolic cross-talk in the tumor microenvironment. EMBO J. 2023;42:e112067.","journal-title":"EMBO J"},{"key":"4731_CR54","doi-asserted-by":"publisher","first-page":"910292","DOI":"10.3389\/fphar.2022.910292","volume":"13","author":"F-J Li","year":"2022","unstructured":"Li F-J, Long H-Z, Zhou Z-W, Luo H-Y, Xu S-G, Gao L-C. System Xc\u2013\/GSH\/GPX4 axis: An important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy. Front Pharmacol. 2022;13:910292.","journal-title":"Front Pharmacol"},{"key":"4731_CR55","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PW, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discovery. 2019;18:358\u201378.","journal-title":"Nat Rev Drug Discovery"},{"key":"4731_CR56","doi-asserted-by":"publisher","first-page":"658399","DOI":"10.3389\/fimmu.2021.658399","volume":"12","author":"T Weber","year":"2021","unstructured":"Weber T. Anti-AAV antibodies in AAV gene therapy: current challenges and possible solutions. Front Immunol. 2021;12:658399.","journal-title":"Front Immunol"},{"key":"4731_CR57","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","volume":"26","author":"C Leborgne","year":"2020","unstructured":"Leborgne C, Barbon E, Alexander JM, Hanby H, Delignat S, Cohen DM, Collaud F, Muraleetharan S, Lupo D, Silverberg J. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020;26:1096\u2013101.","journal-title":"Nat Med"},{"key":"4731_CR58","doi-asserted-by":"publisher","first-page":"e139881","DOI":"10.1172\/jci.insight.139881","volume":"5","author":"ZC Elmore","year":"2020","unstructured":"Elmore ZC, Oh DK, Simon KE, Fanous MM, Asokan A. Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. JCI insight. 2020;5:e139881.","journal-title":"JCI insight"},{"key":"4731_CR59","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s41556-020-0563-3","volume":"22","author":"F Moghadam","year":"2020","unstructured":"Moghadam F, LeGraw R, Velazquez JJ, Yeo NC, Xu C, Park J, Chavez A, Ebrahimkhani MR, Kiani S. Synthetic immunomodulation with a CRISPR super-repressor in vivo. Nat Cell Biol. 2020;22:1143\u201354.","journal-title":"Nat Cell Biol"},{"key":"4731_CR60","doi-asserted-by":"publisher","first-page":"eabd3438","DOI":"10.1126\/scitranslmed.abd3438","volume":"13","author":"YK Chan","year":"2021","unstructured":"Chan YK, Wang SK, Chu CJ, Copland DA, Letizia AJ, Costa Verdera H, Chiang JJ, Sethi M, Wang MK, Neidermyer WJ Jr. Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci Transl Med. 2021;13:eabd3438.","journal-title":"Sci Transl Med"},{"key":"4731_CR61","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1089\/hum.2024.034","volume":"35","author":"T Sato","year":"2024","unstructured":"Sato T, Chaugule S, Greenblatt MB, Gao G, Shim J-H. Advances in Bone-Targeting Drug Delivery: Emerging Strategies Using Adeno-Associated Virus. Hum Gene Ther. 2024;35:329\u201341.","journal-title":"Hum Gene Ther"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04731-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04731-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04731-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:02:56Z","timestamp":1788480176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04731-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4731"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04731-5","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study complied with all the relevant national regulations and institutional policies, was in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine (Approved Number: KY2024088). All animal experiments were performed in accordance with the protocols sanctioned by the Animal Ethical and Welfare Committee (AEWC) at the Shenzhen Glorybay Biomedical Laboratory Animal Center (Approved Number: RW-IACUC-24-0132).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have approved the manuscript and agree with the submission.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"833"}}